COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Avistone develops targeted oncology therapies: MET inhibitor PLB1001 (NMPA conditional approval for MET exon14-skipping NSCLC), EGFR exon20-active PLB1004, and China commercial coverage across 25 provinces and 1,000 hospitals.
